Roles of STAT3 in leukemia (Review)

YIN SHI1,2*, ZHEN ZHANG2*, XINTAO QU3*, XIAOXIAO ZHU2, LIN ZHAO2, RAN WEI2, QIANG GUO2, LINLIN SUN1,2, XUNQIANG YIN1,2, YUNHONG ZHANG1,2 and XIA LI2

1School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences; 2Laboratory for Molecular Immunology, Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan, Shandong 250062; 3Department of Bone and Joint Surgery Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China

Received February 8, 2018; Accepted April 24, 2018

DOI: 10.3892/ijo.2018.4386

Abstract. Leukemia is a type of hematopoietic malignancy, and the incidence rate in the United States and European Union increases by an average of 0.6 to 0.7% annually. The incidence rate in China is approximately 5.17/100,000 individuals, and the mortality rate is 3.94/100,000 individuals. Leukemia is the most common tumor affecting children and adults under 35 years of age, and is one of the major diseases leading to the death of adolescents. Signal transducer and activator of transcription 3 (STAT3) is a vital regulatory factor of signal transduction and transcriptional activation, and once activated, the phosphorylated form of STAT3 (p-STAT3) is transferred into the nucleus to regulate the transcription of target genes, and plays important roles in cell proliferation, differentiation, apoptosis and other physiological processes. An increasing number of studies have confirmed that the abnormal activation of STAT3 is involved in the development of tumors. In this review, the roles of STAT3 in the pathogenesis, diagnosis, treatment and prognosis of leukemia are discussed in the aspects of cell proliferation, differentiation and apoptosis, with the aim to further clarify the roles of STAT3 in leukemia, and shed light into possible novel targets and strategies for clinical diagnosis and treatment.

Contents

1. Introduction
2. The structure and regulation of the activity of STAT3
3. The role of STAT3 in the pathogenesis of leukemia
4. The roles of STAT3 in the diagnosis, treatment and prognosis of leukemia
5. Conclusion

1. Introduction

Leukemia, a common hematological malignancy, originates from clonal leukemia cells with uncontrolled proliferation, blocked cell apoptosis and differentiation disorders. Leukemia is characterized by accumulations of immature leukemic blasts in the bone marrow and hematopoietic tissues, infiltration of non-hematopoietic tissues and organs, and inhibition of normal hematopoietic function. The incidence of leukemia is increasing at an average rate of 0.7% annually in children and adolescents of the United States; in China the incidence of leukemia is approximately 5.17/100,000 individuals and the mortality rate is 3.94/100,000 individuals, which severely endangers the lives of patients (1,2). There are several types of leukemia, and these can be divided into four common types according to cell morphology and biochemical characteristics as follows: Acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) (3). The pathogenesis and clinical treatment for leukemias are ‘hot’ and difficult research directions in the field of cancer. STAT proteins (STATs) belong to a family of transcription factors that are activated by polypeptide ligands, such as cytokines and growth factors. STATs comprise seven members: STAT1, STAT2, STAT3, STAT4, STAT5 (a/b) and STAT6 (4). STAT3 is a crucial member of the STAT family, which forms a dimer following activation, enters the nucleus, and regulates the transcription of diverse target genes (5,6). Since it is closely associated with cell proliferation, differentiation and apoptosis, its abnormal expression and activity are involved in the development of certain diseases, such as hyper-IgE syndrome and developmental abnormalities (7). An increasing number of studies have found that STAT3 abnormal expression and activation are accompanied by leukemia development, which indicates the potential role of STAT3 in the pathogenesis of leukemia (8-11). The present review focuses on the roles of STAT3 in the pathogenesis, diagnosis, treatment and prognosis of different types of leukemia.
2. The structure and regulation of the activity of STAT3

The structure of STAT3. The STAT3 encoding gene is located on the human genome chromosome 17 (17q21.1) and the protein contains six classical functional segments of the STAT family: i) N-terminal domain (ND), which is able to stabilize the dimerized STAT3 and promote the formation of tetramers of two STAT3 dimers to make it more stable with DNA (12); ii) coiled-coil domain (CCD), which mediates STAT3 direct binding to the receptor and facilitates STAT3 phosphorylation on 705-tyrosine site (Y705) (13); iii) DNA binding domain (DBD), which, by recognizing the γ-interferon activating sequence (GAS), will direct STAT3 to the promoters of target genes, and initiate transcriptional activation of the target genes (14); iv) the linker region, the function of which unknown at present; v) Src homology 2 (SH2) domain, the most conserved part of STAT3, which shares the same core sequence ‘GTFLLLRFSS’ with the SH2 domain of tyrosine kinase Src, and the phosphorylation and subsequent dimerization of SH2 domain and plays a critical role in the process of signal transduction (15); vi) C-terminal transcriptional activation domain (TAD), in which there are several important tyrosines/serines located or near the region, and the phosphorylation of specific residues are important for STAT3 function. For example, Y705 is located between SH2 and TAD, which is crucial for STAT3 activation and dimerization, and the 727-serine site (S727) is located in TAD, which is thought to enhance the transcriptional activity of STAT3 (16-18) (Fig. 1A).

STAT3 has four isoforms: STAT3α, STAT3β, STAT3γ and STAT3β. Among the structures of STAT3 isoforms, STAT3α is the most common structure. It consists of the ND, CCD, DBD, SH2 and TAD domains, with a molecular weight of approximately 92 kDa, and is mainly associated with cell proliferation and transformation (19,20) (Fig. 1A). STAT3β originates from the alternative splicing of the STAT3 gene transcript, which results in a 55 amino acid deletion at the 3’ end of the open reading frame of STAT3α with a molecular weight of approximately 83 kDa; STAT3β lacks the C-terminal transactivation domain and S727, and acts as a dominant transcriptional inhibitory factor that is particularly crucial for granulocyte colony-stimulating factor (G-CSF)-mediated cell differentiation (21-23) (Fig. 1B). STAT3γ, with molecular weight of 72 kDa, acts as a dominant negative form of STAT3α. It lacks the C-terminal transactivating portion, and due to controlled proteolysis, the corresponding residues of S727 and Y705 of STAT3α are absent in STAT3γ, which retains the SH2 domain and can be recruited to tyrosine-phosphorylated receptor proteins through the SH2 domain (Fig. 1C). STAT3γ is predominantly activated in terminal differentiated neutrophils, and is involved in the regulation of cell proliferation (19,24). Stat3β, a putative isoform of STAT3 with a yet unknown structure, has been found to be expressed during the early stage of granulocytic differentiation (25).

The regulation of STAT3 activity. STAT3 can be activated through a number of mechanisms, including through the Janus kinase (JAK)/STAT3, Ras/mitogen-activated protein kinase (MAPK) and non-receptor tyrosine kinase signaling pathways (26,27). STAT3 is negatively regulated by two types of regulating factors, including the suppressor of cytokine signaling (SOCS) and the protein inhibitor of activated STAT (PIAS), which regulate the active status of STAT3 through different mechanisms (28). These activation pathways and regulatory factors regulate STAT3 activity and function synergistically, and play essential roles in physiological and pathological processes (29-31) (Fig. 2). A description of these activation pathways and regulatory factors is provided as follows:

a) The JAK/STAT3 pathway. The Janus kinase (JAK) family consists of four non-receptor tyrosine kinases, JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2), which not only phosphorylate the bound cytokine receptors, but also a number of signaling molecules, which contain specific SH2 domains (32). Different cytokine receptors on the cell membrane bind the corresponding ligands to form homologous or heterodimers, which drive the mutual phosphorylation of the JAKs in proximity and facilitate the activation of STAT3 (33-38) (Table I). Mechanistically, the activated JAKs will phosphorylate tyrosine residues on the receptor, which provides a ‘docking site’ with the surrounding amino acid sequence for STAT3 protein recruitment by SH2 domain. Subsequently, STAT3 protein is phosphorylated by JAKs predominantly at the Y705 site, leading to the activation and dimerization of STAT3, which will rapidly enter the nucleus, specifically bind to the GAS sequence (TTC/ANNG/TA) or the interferon-stimulated response element sequence (AGTTTCNNTTCCN/T), and initiate the activation and transcription of target genes (13,39,40). In addition, the activity of STAT3 in the nucleus needs to be tightly controlled. For example, STAT3 activity can be ‘shut down’ by the dephosphorylation effects of tyrosine phosphatase in the nucleus, or by proteolytic enzyme degradation of STAT3 protein.

b) The Ras-MAPK activation pathway. The role of Ras signaling in STAT3 activation has been demonstrated by numerous studies, whereby the Ras-induced activation of MAPKs and the subsequent MAPK-mediated phosphorylation of STAT3 may be required for STAT3 activity (41). The MAPK family includes extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinase (JNK) and p38 MAPK (p38), which act as components in the Ras signaling pathway with serine/threonine protein kinase activity (27). STAT3 is one of the MAPK substrates, and the MAPK-mediated phosphorylation of STAT3 on S727 will lead to STAT3 dimerization, its entry into the nucleus, its binding to specific DNA sequences in the promoters of genes, and the initiation of the activation and transcription of target genes; when MAPK is blocked, the promoting effects of STAT3 on target gene transcription are significantly decreased (42).

c) Non-receptor tyrosine kinase signaling pathways. In addition to JAK/STAT3 and Ras/MAPK pathways, non-receptor tyrosine kinases, such as activated Src kinase and Abelson leukemia protein (Abl) can also directly phosphorylate STAT3 protein independently of ligand-induced receptor pathways. The activation of non-receptor tyrosine kinase signaling pathways also causes the simultaneous activation of MAPK family members, including p38, ERK and JNK, which phosphorylate STAT3 on S727 in the C-terminal transactivation domain. Following entry into the nucleus, the activated STAT3 proteins bind to specific DNA-response elements in...
Figure 1. The structure of signal transducer and activator of transcription 3 (STAT3) isoforms. (A) STAT3α is the full-length STAT3 protein, which consists of the N-terminal domain (ND), coiled-coil domain (CCD), DNA binding domain (DBD), Linker, Src homology 2 (SH2) and C-terminal transcriptional activation domain (TAD). (B) STAT3β is the truncated form of STAT3α, which lacks TAD and S727 compared to STAT3α. (C) STAT3γ is the truncated form of STAT3α, which lacks TAD, S727 and Y705.

Figure 2. Regulation of STAT3 activity. STAT3 can be activated by the Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3), Ras/mitogen-activated protein kinase (MAPK) and non-receptor tyrosine kinase signaling pathways. STAT3 is negatively regulated by the suppressor of cytokine signaling (SOCS) and protein inhibitor of activated STAT3 (PIAS3), which regulate the activity status of STAT3.
SHI et al.: ROLES OF STAT3 IN LEUKEMIA

the promoters of genes and initiate the expression of unique genes through interactions with other transcriptional regulatory components (27,41).

d) **SOCS and PIAS regulatory pathways.** STAT3 activity is negatively regulated by two major regulators, SOCS and PIAS (28). The SOCS family consists of eight members: SOCS1-7 and cytokine-inducible SH2-containing protein (CISH), and they negatively regulate the JAK/STAT3 signaling pathway via several mechanisms as follows: 

i) All SOCSs bind to receptor complexes or associated JAKs through their SH2 domains, recruit Elongin B/C heterodimers, Cullin5 and other components of an E3 ubiquitination complex, and lead to the degradation of receptors or associated JAKs via the proteasomal pathway; 

ii) SOCS1 and SOCS3 directly inhibit JAKs tyrosine activity via their kinase inhibitory region by binding to the JAK activation loop; 

iii) CISH, SOCS2 and SOCS3 can inhibit signaling transduction via their ability to bind to phosphotyrosine residues on receptors, thereby blocking the binding of other SH2-containing signaling molecules (JAKs/STAT3) to the receptors; 

iv) SOCS7 can prevent the nuclear translocation of p-STAT3, and inhibit the transcription of target genes (43,44).

PIAS3 is currently known to be associated with STAT3 activity in the PIAS family, which affects STAT3 activation via several molecular mechanisms as follows: 

i) PIAS3 may inhibit transcription by blocking the DNA-binding activity of p-STAT3; 

ii) PIAS3 may suppress transcription by recruiting other co-regulators, such as histone deacetylases; 

iii) PIAS3 may regulate transcription by promoting the sumoylation of p-STAT3; 

iv) PIAS3 may suppress transcription by sequestering p-STAT3 to certain subnuclear structures where co-repressor complexes are enriched (45).

3. The role of STAT3 in the pathogenesis of leukemia

Leukemia cells and normal hematopoietic cells in the same bone marrow microenvironment have entirely different biological characteristics; normal hematopoietic cells, under the stimulation of cytokines, will continue to differentiate and mature; however, leukemia cells are characterized by differentiation failure and infinite proliferation. In normal cells, the activation of STAT3 is rapid and transient; however, in leukemia cells, abnormal STAT3 expression and activation always occur, which accelerate leukemia cell proliferation, block leukemia cell differentiation and inhibit leukemia cell apoptosis, leading to the occurrence and development of leukemia (46).

**STAT3 and leukemia cell proliferation.** In the process of leukemia cell proliferation, STAT3 can promote the proliferation of leukemia cells through JAK/STAT3, Ras/Raf/MAPK, PI3K/AKT/mammalian target of rapamycin (mTOR) and other signaling pathways. For example, G-CSF stimulates the activation of STAT3 to promote the proliferation of AML cell lines (47), and protein kinase CK2 regulates the transcription of the Forkhead box O3 (FOXO3a) gene by activating STAT3 through JAK/STAT3 and PI3K/AKT/mTOR, and promotes the proliferation of leukemia stem cells (48). Moreover, STAT3 can also be activated via the JAK/STAT3 and Ras/Raf/MAPK pathways.

---

**Table I. Receptor-specific JAKs in the JAK/STAT3 pathway.**

<table>
<thead>
<tr>
<th>Receptors</th>
<th>JAKs</th>
<th>(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type II cytokine receptor</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interleukin-10 receptor</td>
<td>JAK1, TYK2</td>
<td>(33)</td>
</tr>
<tr>
<td><strong>Receptor tyrosine kinase family</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epidermal growth factor receptor</td>
<td>JAK1, JAK2</td>
<td>(34)</td>
</tr>
<tr>
<td>Platelet-derived growth factor receptor</td>
<td>JAK1, JAK2, TYK2</td>
<td>(34)</td>
</tr>
<tr>
<td>Colony stimulating factor 1 receptor</td>
<td>JAK1, TYK2</td>
<td>(35)</td>
</tr>
<tr>
<td>Vascular endothelial growth factor receptor</td>
<td>TYK2</td>
<td>(36)</td>
</tr>
<tr>
<td><strong>Receptors with gpl30 domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interleukin-6 receptor</td>
<td>JAK1, JAK2, TYK2</td>
<td>(33)</td>
</tr>
<tr>
<td>Interleukin-11 receptor</td>
<td>JAK1, JAK2, TYK2</td>
<td>(33)</td>
</tr>
<tr>
<td>Oncostatin M receptor</td>
<td>JAK1, JAK2, TYK2</td>
<td>(37)</td>
</tr>
<tr>
<td>Leukemia inhibitory factor receptor</td>
<td>JAK1, JAK2, TYK2</td>
<td>(37)</td>
</tr>
<tr>
<td>Ciliary neurotrophic factor receptor</td>
<td>JAK1, JAK2</td>
<td>(35)</td>
</tr>
<tr>
<td>Granulocyte colony-stimulating factor receptor</td>
<td>JAK1, JAK2, TYK2</td>
<td>(38)</td>
</tr>
<tr>
<td>Cardiotrophin-1 receptor</td>
<td>JAK1, JAK2</td>
<td>(35)</td>
</tr>
<tr>
<td><strong>Receptors with γc domain</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interleukin-2 receptor</td>
<td>JAK1, JAK3</td>
<td>(33)</td>
</tr>
<tr>
<td>Interleukin-7 receptor</td>
<td>JAK1, JAK3</td>
<td>(35)</td>
</tr>
<tr>
<td>Interleukin-9 receptor</td>
<td>JAK1, JAK3</td>
<td>(33)</td>
</tr>
<tr>
<td>Interleukin-15 receptor</td>
<td>JAK1, JAK3</td>
<td>(35)</td>
</tr>
</tbody>
</table>

JAK, Janus kinase; STAT3, signal transducer and activator of transcription 3; TYK, tyrosine kinase.
pathways, which initiates the transcription of the Forkhead box M1 (FOXM1) gene and promotes the proliferation of the CML cell line, K562 (49), whereas the inhibition of STAT3 activity can effectively reduce the proliferation and survival of leukemia cells (50-52). For example, the STAT3 inhibitor, nifuroxazide, and the PI3K inhibitor, GDC-0032, alone or in combination, have been shown to effectively reduce the proliferation of human ALL CCRF-CEM cells (50). In CD34 antigen-positive AML (AML CD34+) cells, the siRNA-mediated knockdown of STAT3 has been shown to significantly inhibit the growth and survival of AML CD34+ cells (51). In addition, it has been demonstrated that the combined use of the survivin gene inhibitor, YM155, with the STAT3 inhibitor, S3I-201, significantly inhibits the proliferation of YM155-tolerant human T lymphocytic leukemia MT-2 cells (52). These studies collectively suggest that STAT3 overexpression can promote leukemia cell proliferation and that the inhibition of STAT3 activity can reduce leukemia cell survival and proliferation (Fig. 3).

**STAT3 and leukemia cell differentiation.** Hematopoietic progenitor cells can be divided into myeloid and lymphoid progenitor cells. Myeloid progenitor cells have the potential to multi-differentiate into myeloid cells (erythrocytosis, granulocytosis, thrombocytosis, etc.), while lymphoid progenitor cells have the potential to differentiate into lymphatic subfamilies. Leukemia cells, due to differentiation and maturity disorders, are always accompanied by abnormal hyperplasia, and are stagnated at different stages of cell development. For example, acute leukemia (AL) cell differentiation is stagnated at the relatively earlier stages, and the majority of AL cells are progenitor cells and early immature cells; chronic leukemia (CL) cell differentiation is stagnated at the later stages, and the majority of CL cells are mature naive cells or mature cells. We hereby discuss the roles of STAT3 in the differentiation of leukemia cells as follows:

a) **STAT3 in granulocyte differentiation and its role in leukemia.** Granulocyte differentiation involves a variety of cytokines and transcription factors, of which G-CSF plays an essential role during the process. The binding of G-CSF to the G-CSF receptor (G-CSFR) causes the intracellular phosphorylation of the Y705 domain of STAT3 and the activation of multiple signal transduction pathways, including Ras/Raf/MITK, PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathways, and the inhibition of STAT3 activity can reduce the proliferation and survival of leukemia cells.

**Figure 3.** Roles of signal transducer and activator of transcription 3 (STAT3) in the proliferation of leukemia cells. STAT3 can promote the proliferation of leukemia cells through the Janus kinase (JAK)/STAT3, Ras/Raf/mitogen-activated protein kinase (MAPK), PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathways, and the inhibition of STAT3 activity can reduce the proliferation and survival of leukemia cells.
granulocytic progenitors into granulocytes (54,56,57) (Fig. 4). However, it should be noted that isoforms of STAT3 may function differently during G-CSF-directed granulocyte differentiation. It has been reported that G-CSF activates STAT3α in three of six uncultured AML patient samples and in all examined AML cell lines, apart from HL-60. G-CSF directs the differentiation of CD34+ bone marrow cells and HL-60 cells into granulocytes without affecting STAT3α activity, but only increasing STAT3β activity. These results demonstrate that the balance of the two isoforms of STAT3 in myeloid cells may influence gene activation and the ability of these cells to differentiate in response to G-CSF (47). In addition, other researchers have revealed that the expression and activation of STAT3s is altered in a maturation stage-specific manner. During the process of granulocyte differentiation, the ratio of isoforms shifts from predominantly STAT3α to STAT3β. Concomitant with STAT3α protein downregulation in different stages of granulocyte differentiation, the expression of STAT3γ is upregulated inversely. STAT3δ protein is expressed at low levels and is reduced with differentiation, but is primarily phosphorylated during an intermediate stage of maturation (25).

The role of STAT3 in the process of leukemia cell differentiation into granulocytes is increasingly valued. Xu et al (58) observed that the fusion protein TAT-CT3 induced the committed differentiation of the human acute promyelocytic leukemia (APL) cell line, HL-60, into granulocytes, and TAT-CT3 transiently promoted an elevation in STAT3 phosphorylation, which resulted in the STAT3 dimer entering the nucleus and promoting the expression of the Bic gene. STAT3 also plays a role in controlling the H3K27me3 modification of the Bic gene promoter, through which it reduces Bic transcription, and suppresses miR-155 transcription and finally results in an elevation in SOCS-1 levels, which further inhibits STAT3 phosphorylation in a feedback loop for a long-term period to promote HL-60 cell differentiation into granulocytes (58). Moreover, in another study, in the process of the all-trans retinoic acid (ATRA)-induced differentiation of the APL cell line, HT93A, into granulocytes, the expression levels of total and phosphorylated STAT3 were significantly reduced, which further suggested that the inhibition of STAT3 expression and activation would promote the granulocyte-oriented differentiation of leukemia cells (59).

b) Involvement of STAT3 in monocyte/macrophage differentiation and its role in leukemia. Monocytes originate from granulocyte-monocyte progenitor cells in bone marrow and are transported through the blood; they migrate into the tissues, where they are transformed into macrophages, and macrophages can be polarized into two subgroups: M1 and M2. M1 macrophages mainly secrete tumor necrosis factor (TNF)-α, interleukin (IL)-6 and other cytokines, exerting pro-inflammatory and antitumor effects; M2 macrophages, which are...
characterized by the overexpression of arginase 1 and IL-4 receptor α (IL-4Rα), mainly secrete IL-4, IL-10 and other cytokines, and play important roles in diverse biological processes, including anti-inflammation, tissue repair and tumor promotion (60-63). It has been reported that IL-6, in combination with macrophage colony stimulating factor (M-CSF), can induce CD14+ monocyte differentiation into M2-like phenotype macrophages in vitro, and during the process, the phosphorylated levels of STAT3 were found to be significantly increased, which suggests that STAT3 can induce the committed differentiation of mononuclear cells into M2 macrophages and exert pro-tumor functions (64). Moreover, Komohara et al. (65) reported that upon co-culture with primary central nervous system lymphoma cells, macrophages exhibited a greater STAT3 phosphorylation and acquired the M2 phenotype, which indicated that STAT3 activation may also be involved in the promotion of macrophage M2 polarization, and tumor occurrence and development.

The roles of STAT3 in the process of leukemia cell differentiation into monocytes/macrophages have been increasingly investigated by researchers. It has been found that IL-6 activates STAT3 to bind to and initiate the transcription of the target genes, c-myc and c-myb, through the GAS sequence in the promoter, and thus promotes M1-type mouse myeloid leukemia cell differentiation into mononuclear cells. Moreover, leukemia inhibitory factor receptor-chain LIFRα-CT3 activates STAT3 through the JAK2/STAT3 pathway, which leads to the expression of CD11b and CD14 on the surface of HL-60 cells and suggests that the activation of STAT3 can promote the differentiation of HL-60 cells into monocytes (71). However, studies have also found that the siRNA- or shRNA-mediated knockdown of STAT3 in HL-60 cells results in a decreased PRL-3 gene expression and an increased expression of the cell surface markers, CD11b and CD14, which indicates the dual roles of STAT3 in the regulation of leukemia cell differentiation; thus, the specific mechanisms warrant further investigation (72) (Fig. 5).

However, STAT3 has yet not been validated to play a role in the process of leukemia cell differentiation into M1/M2 subgroup macrophages.

c) STAT3 in DC differentiation and its role in leukemia. Dendritic cells (DCs) originate from multifunctional hematopoietic stem cells, and are the most important antigen-presenting

Figure 5. Roles of signal transducer and activator of transcription 3 (STAT3) in the differentiation of murine M1 myeloid leukemia cells/HL-60 cells into monocytes/macrophages. The dual roles of STAT3 were depicted in the regulation of leukemia cells differentiation into monocytes/macrophages.
cells (APCs) in vivo, which play crucial roles in tumor surveillance, pathogenic microbial infection resistance and internal environmental stability maintenance (73,74). Patients with leukemia with a defective DC number and function cannot effectively stimulate the adaptive immune response or eliminate leukemia cells (75). Thus, if the committed differentiation of leukemia cells into DCs could be induced, which would probably express leukemia-specific antigens on the membrane, this would directly present the leukemia antigens to the T-cells, and then kill leukemia cells (76). DC development is highly dependent upon fms-like tyrosine kinase 3 ligand/fms-like tyrosine kinase 3 (Flt3L/Flt3) signaling, and the interaction of Flt3L/Flt3 activates STAT3 via JAK, which subsequently promotes the transcription of regulatory factor E-box protein, and promotes DC differentiation (77-80). Brady et al. observed that STAT3 phosphorylation levels were significantly increased upon human granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-4 treatment during the process of differentiation into DCs for the AML cell lines, HEL, KG-1 and MUTZ-3, which suggested that the constitutive STAT3 activation may promote the differentiation of leukemia cells into DCs and the intervention of STAT3 activity may have great prospects in modulating the process of the committed differentiation of leukemia cells into DCs for leukemia treatment.

**STAT3 and leukemia cell apoptosis.** The occurrence of leukemia is closely related to the apoptotic disorder of leukemia cells. STAT3 plays a key role in leukemia cell apoptosis. In general, STAT3 activation can inhibit the apoptosis of leukemia cells by inducing anti-apoptotic gene expression. For example, internal tandem duplication (ITD) in the juxtaembrane in the kinase domain of Flt3 is a common genetic lesion in AML, and the stimulation of the Flt3-ITD AML cells, MV4-11, results in the elevation of p-STAT3 levels, which upregulates the expression of pro-apoptotic genes, c-IAP2, to protect AML cells from apoptosis (82). In the CML cell line, K562, the expression levels of the anti-apoptotic genes, Bcl-2, Bcl-xL, Bcl-1 and survivin and those of the inhibitor of apoptosis protein, c-IAP2, have been shown to be upregulated by STAT3 activation to protect K562 cells from apoptosis (83). In CLL cells, the expression levels of the anti-apoptotic genes, Bcl-2, Bcl-xL, cyclin D1 (CCND1) and ROR1, were upregulated following the activation of STAT3, and protected CLL cells from apoptosis (84) (Fig. 6A). The inhibition of STAT3 expression can upregulate the expression of pro-apoptotic genes and induces leukemia cell apoptosis. For example, in K562 cells, the STAT3-specific inhibitor, LLL-3, has been shown to induce leukemia cell apoptosis by activating the caspase-3- and -7-mediated pro-apoptotic pathway (85). In TEL-AML1 fused ALL, the STAT3 inhibitor, S3I-201, has been shown to induce leukemia cell apoptosis by upregulating the expression of the pro-apoptotic genes, caspase-3, -8 and -9 (86). The cytotoxic agent, bromo analogue (TBr), has been shown to enhance the expression of the pro-apoptotic genes caspase-3, -8 and -9, and to decrease the ratio of the anti-apoptotic genes, Bcl-2/Bax, by downregulating p-STAT3 and upregulating p-ERK to induce the apoptosis of HL-60 cells (87). Moreover, (R)-5-hydroxy-2-methylchroman-4-one (HMC), isolated from a novel endophytic fungus, can significantly reduce the level of p-STAT3, which activates the pro-apoptotic genes, Bax, Bid, caspase-3, -8 and -9 to induce leukemia cell apoptosis (88) (Fig. 6B). However, a previous study reported that the overexpression of STAT3 in CLL upregulates caspase-3 expression, and induces CLL cell apoptosis (89), suggesting that different activation status of STAT3 may play differential roles in the regulation of leukemia cell apoptosis.

In summary, STAT3 is closely related to the development of leukemia. It plays essential roles in the development of leukemia by promoting the proliferation of leukemia cells (Fig. 7A), regulating the differentiation of granulocytes, monocytes/macrophages and dendritic cells and blocking the apoptosis of leukemia cells (Fig. 7B and C). The STAT3 expression and activation status may thus be an important target for leukemia treatment and prognosis assessment.

### 4. The roles of STAT3 in the diagnosis, treatment and prognosis of leukemia

The sustained activation of the STAT3 gene plays an important role in the development of leukemia; it can be used as an important target in the early diagnosis, treatment and prognosis of leukemia.

**The role of STAT3 in the diagnosis of leukemia.** STAT3 plays an important role in the diagnosis of leukemia. For example, Xia et al. (90) found that in patients newly diagnosed with AML, 13 out of 17 patients were found to exhibit the constitutive phosphorylation of STAT3 on Y705. Stevens et al. (91) demonstrated that the STAT3 pathway was more sensitive to ligand stimulation in patients with relapsing AML. Bennici et al. reported that constitutively active STAT3 was detected in ten of 36 patients newly diagnosed with AML (92), and in another study, almost 78% of the patients (21 of 27) expressed STAT3β protein (25).

Thus, collectively, it is suggested that STAT3 plays an important diagnostic role in both newly diagnosed and relapsing AML. T-cell large granular lymphocytic leukemia (T-LGLL) sustains the phosphorylation of STAT3, and mutations of the STAT3 gene have been identified as a recurrent genetic abnormality in T-LGLL (93-99).

STAT3 single nucleotide polymorphisms (SNPs) are also prospective candidates for use in predicting susceptibility to leukemia, which is associated with the individual sensitivity of leukemia and is important for leukemia diagnosis. For example, Zhong et al. (100) investigated association between STAT3 SNPs and leukemia, and found that rs17886724 located on STAT3 intron 4 was closely related to the pathogenesis of leukemia; Lautner-Csorba et al. (101) found that two SNPs of rs3816769 and rs12949918 in the gene have been identified as recurrent genetic abnormalities (≥50 chromosomes). All these studies indicate the significance of STAT3 in the diagnosis of leukemia.

**The role of STAT3 in the treatment of leukemia.** STAT3 plays an important role in leukemia, and STAT3 intervention is currently a ‘hot’ topic of research, which may reveal novel targets and strategies for leukemia treatment (102,103). At present, different types of STAT3 inhibitors have been implemented for leukemia treatment, including STAT3 SH2 domain inhibitors, DNA-binding domain inhibitors, STAT3
gene expression oligonucleotide inhibitors and N-terminal domain inhibitors (104). For example, small molecule C188-9, a STAT3 inhibitor, has been shown to induce the apoptosis of multiple AML cell lines and primary cells (8). The STAT3 inhibitor, OPB-31121, has also been shown to strongly inhibit STAT3 and STAT5 phosphorylation, and to exert a significant anti-proliferative effect on human leukemia cells (105). In addition, a number of chemotherapy drugs can also target STAT3 to exert a therapeutic effect. For instance, decitabine has been shown to markedly inhibit the proliferation of HL-60 cells and to enhance the cytotoxicity of natural killer cells to HL-60 cells, which may be related to the STAT3 signaling pathway (106). Zoledronic acid and bortezomib can both inhibit the proliferation of K562 cells and induce apoptosis via the STAT3 signaling pathway (107,108). Chidamide has been shown to affect AML cell viability by inhibiting the JAK2/STAT3 signaling pathway (109). Although some inhibitors have been shown to be effective in the treatment of leukemia in vitro, few inhibitors of STAT3 have been approved for leukemia therapy in clinical practice (Table II).

Moreover, many natural extracts of traditional Chinese medicine have also been shown to inhibit the activation of STAT3 to exert antitumor effects. For instance, the traditional Chinese medicine, cucurbitacin B, has been shown to inhibit STAT3 activation along with the Raf/MEK/ERK pathway and to promote the apoptosis of K562 cells (110). It has also been demonstrated that dehydrocostus lactone significantly suppresses the proliferation of K562 cells by inhibiting STAT3 phosphorylation and the expression of downstream target genes (111). Tanshinone IIA and cryptotanshinone have been shown to induce K562 cell apoptosis by modulating JAK/STAT3/5 and SHP1/2 signaling distinctively (112). Matrine suppresses the growth of human CLL cells via its inhibition of the IL-6/JAK/STAT3 signaling (113). On the whole, traditional Chinese medicine has great potential in the treatment of leukemia. It has also been reported that certain biological
Table II. STAT3 inhibitors.

<table>
<thead>
<tr>
<th>STAT3 inhibitor</th>
<th>Targeted domain</th>
<th>Effect on leukemia treatment (pre-clinical)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ST3-H2A2</td>
<td>The N-terminal</td>
<td>Unknown</td>
</tr>
<tr>
<td>BP-1-102</td>
<td>The SH2</td>
<td>Unknown</td>
</tr>
<tr>
<td>BP-5-087</td>
<td>The SH2</td>
<td>Yes</td>
</tr>
<tr>
<td>Catechol</td>
<td>The SH2</td>
<td>Unknown</td>
</tr>
<tr>
<td>C188-9</td>
<td>The SH2</td>
<td>Yes</td>
</tr>
<tr>
<td>ISS 610</td>
<td>The SH2</td>
<td>Unknown</td>
</tr>
<tr>
<td>LLL-3</td>
<td>The SH2</td>
<td>Yes</td>
</tr>
<tr>
<td>LLL12</td>
<td>The SH2</td>
<td>Unknown</td>
</tr>
<tr>
<td>MM-206</td>
<td>The SH2</td>
<td>Yes</td>
</tr>
<tr>
<td>OPB-31121</td>
<td>The SH2</td>
<td>Yes</td>
</tr>
<tr>
<td>OPB-51602</td>
<td>The SH2</td>
<td>Yes</td>
</tr>
<tr>
<td>STA-21</td>
<td>The SH2</td>
<td>Yes</td>
</tr>
<tr>
<td>Stattic</td>
<td>The SH2</td>
<td>Yes</td>
</tr>
<tr>
<td>S31-201</td>
<td>The SH2</td>
<td>Unknown</td>
</tr>
<tr>
<td>S31-201.1066</td>
<td>The SH2</td>
<td>Unknown</td>
</tr>
<tr>
<td>S31-M2001</td>
<td>The SH2</td>
<td>Unknown</td>
</tr>
<tr>
<td>STX-0119</td>
<td>The SH2</td>
<td>Yes</td>
</tr>
<tr>
<td>S31-1757</td>
<td>The SH2</td>
<td>Unknown</td>
</tr>
<tr>
<td>5,15-DPP</td>
<td>The SH2</td>
<td>Unknown</td>
</tr>
<tr>
<td>CPA-1</td>
<td>DNA binding</td>
<td>Unknown</td>
</tr>
<tr>
<td>CPA-7</td>
<td>DNA binding</td>
<td>Unknown</td>
</tr>
<tr>
<td>DBD-1</td>
<td>DNA binding</td>
<td>Unknown</td>
</tr>
<tr>
<td>InS3-54</td>
<td>DNA binding</td>
<td>Unknown</td>
</tr>
<tr>
<td>IS3-295</td>
<td>DNA binding</td>
<td>Unknown</td>
</tr>
<tr>
<td>Platinum (IV) tetrachloride</td>
<td>DNA binding</td>
<td>Unknown</td>
</tr>
<tr>
<td>Atovaquone</td>
<td>Unknown</td>
<td>Yes</td>
</tr>
</tbody>
</table>

therapies can also be used to target STAT3 signaling pathways for leukemia treatment. Lentivirus-mediated STAT3 silencing may inhibit the expression of its downstream genes, \( c\)-myc, \( Bcl-\alpha\) and \( cycin 1\), to suppress the malignant biological behaviors, and STAT3 silencing also inhibits the leukemogenic potency of K562 cells in mice (114). Moreover, the suppression of the \( survivin\) gene induced by the BCR/ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs (115). Thus, the role of biological therapy in the treatment of leukemia cannot be ignored.

The role of STAT3 in the prognosis of leukemia. The roles of STAT3 in the prognosis of leukemia have drawn increasing attentions, but are still controversial. Recent studies have found that \( Mcl-1\) gene expression and indoleamine 2,3-dioxygenase 1 (IDO1) activity can both be regulated by STAT3 which are associated with the poorer prognosis of leukemia (116,117). Bruserud et al (103) examined the association between STAT3 expression in bone marrow and the prognosis of patients with AML, and found that STAT3 expression and Y705 activation had an adverse prognostic impact on human AML. Moreover, Adamaki et al (118) discovered that 8 out of 14 childhood patients with ALL, in which STAT1 and STAT3 were expressed at lower levels on day 33, were relapse-free with a high survival rate, indicating that STAT3 gene upregulation is a poor predictor of the clinical prognosis of childhood ALL. Furthermore, Zhong et al (119) investigated the association between genomic polymorphisms of STAT3 and AML patient response to chemotherapy in a Chinese population, and found that there were strong associations between unfavorable cytogenetics, partial remission (and even no remission) and GG genotype frequency in rs9909659, which suggested that the STAT3 GG genotype in rs9909659 may confer an enhanced resistance to standard chemotherapy, and predict an unfavorable prognosis. Besides, it has also been reported that constitutive STAT3 activation is associated with the shortest disease-free survival in AML, and the subgroup of AML patients, which expressed STAT3β and showed constitutive activity of STAT3, experienced a particularly poor outcome (92).

By contrast, some studies have suggested that p-STAT3 also has a beneficial effect on the prognosis of leukemia. Redell et al (8,120) discovered that when the phosphorylated level of STAT3 on Y705 and S727 increased in AML upon cytokine stimulation, the disease-free and survival rates of patients were improved. Levidou et al (121) discovered that the immunoreactivity of tyrosine phosphorylated STAT3 was marginally associated with a prolonged overall survival. In addition, the upregulation of tyrosine phosphorylated STAT3 was associated with a longer time to first treatment, and the absence of p-STAT3 was associated with a shorter time to progression, which indicated that p-STAT3 also has a favorable prognostic effect on leukemia. Nevertheless, the upregulation of STAT3 is also associated with the favorable prognosis of AL (122). Collectively, the impact of STAT3 on the prognosis of leukemia remains controversial. Due to the defects of current clinical studies, including small sample sizes and so on, extensive clinical studies are warranted in order to further confirm the role of STAT3 in the evaluation of the prognosis of leukemia.

5. Conclusion

STAT3 is an important signal transducer and activator of transcription, which is widely involved in cell physiological processes, such as cell proliferation, differentiation and apoptosis through a variety of signal transduction pathways, and plays key roles in the occurrence of cancer and other diseases. In this review, the roles of STAT3 in the pathogenesis, diagnosis, treatment and prognosis of leukemia were reviewed and discussed in the aspects of cell proliferation, committed cell differentiation and apoptosis. There is increasing evidence to indicate that STAT3 expression and activity abnormalities will lead to excessive proliferation, differentiation disorders and the abnormal apoptosis of leukemia cells, which may provide a novel new biomarker for the clinical diagnosis, treatment and prognosis evaluation of leukemia. At present, the roles of upstream factors modulating STAT3 expression and activity, and the signaling pathways mediated by downstream target genes are not yet clear during the process of leukemia development. The in-depth exploration of this area, particularly in the perspective of epigenetic regulation, may further reveal the roles of STAT3 in the pathogenesis of leukemia and the essential regulatory mechanisms.
Acknowledgements
Not applicable.

Funding
This study was supported by the Natural Science Foundation of China (grant nos. 81373670, 81673981, 81573467, 81601442 and 81704116), the Primary Research and Development Plan of Shandong Province (grant nos. 2016GSF202016, 2017GSF19118 and 2017GSF218013), the Project of Transformation in High-tech Achievements (grant no. 2013ZHHZX2A0405), the Natural Science Foundation of Shandong Province (grant no. ZR2017PH008 and ZR2018PH042), the Science and Technology Development Grant of the State Administration of traditional Chinese medicine of Shandong Province (grant nos. 2013-2016 and 2017-174), the Family Planning Committee of Shandong Province (grant no. [2014]14), the Project for Shandong Medical and Health Science and Technology Plan (grant no. 2015WS0191 and 2016WS0524), the Project of Science and Technology of Shandong Academy of Medical Sciences (grant nos. 2016-34, 2016-35 and 2017-15) and the Innovation Project of Shandong Academy of Medical Sciences.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors' contributions
YS, ZZ, XQ, XZ and LZ searched the literature for STAT3 roles in leukemia; RW, XY and YZ screened the literature for STAT3 inhibitors; YS, ZZ, QG and LS drew the graphics; XL conceived the project, and YS, ZZ and XL wrote the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
31. Bournaoud E and Bromberg J: Targeting the tumor microenvi-
ronment: LIFRα signaling. JAK-STAT 2; e23828, 2013.
33. Schindler C and Strehlow I: Cytokines and STAT signaling. Adv
34. Pastuscheck J, Poetzsch J, Morales-Prieto DM, Schleussner E,
Markert UR and Georgiev G: Stimulation of the Jak/STAT
35. Trengove MC and Ward AC: SOCS proteins in development and
37. Schindler C and Strehlow I: Cytokines and STAT signaling. Adv
38. Mariano VJ and Roguin LP: The granulocyte colony stimu-
39. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE,
Wentzel AL, Xi S and Grands JR: STaT3 activation abrogates
40. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE,
Wentzel AL, Xi S and Grands JR: STaT3 activation abrogates
growth factor dependence and contributes to head and neck squamous
cellular carcinoma tumor growth in vivo. Cell Growth
41. Ram PT and Iyengar R: G protein coupled receptor signaling
through the Src and Stat3 pathway: Role in proliferation and
42. Ahmed ST and Ivashkiv LB: Inhibition of IL-6 and IL-10
43. Pastuscheck J, Poetzsch J, Morales-Prieto DM, Schleussner E,
Markert UR and Georgiev G: Stimulation of the Jak/STAT
44. Ahmed ST and Ivashkiv LB: Inhibition of IL-6 and IL-10
45. Schindler C and Strehlow I: Cytokines and STAT signaling. Adv
46. Ma LD, Zhou M, Wen SH, Ni C, Jiang LJ, Fan J and Xia L:
47. Ma LD, Zhou M, Wen SH, Ni C, Jiang LJ, Fan J and Xia L:
48. Mancalha AL, Binato R, Ferreira GM, Du Rocher B and
49. Mancalha AL, Binato R, Ferreira GM, Du Rocher B and
50. Schindler C and Strehlow I: Cytokines and STAT signaling. Adv
51. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE,
Wentzel AL, Xi S and Grands JR: STaT3 activation abrogates
growth factor dependence and contributes to head and neck squamous
42. Ahmed ST and Ivashkiv LB: Inhibition of IL-6 and IL-10
43. Pastuscheck J, Poetzsch J, Morales-Prieto DM, Schleussner E,
Markert UR and Georgiev G: Stimulation of the Jak/STAT
44. Ahmed ST and Ivashkiv LB: Inhibition of IL-6 and IL-10
45. Schindler C and Strehlow I: Cytokines and STAT signaling. Adv
46. Ma LD, Zhou M, Wen SH, Ni C, Jiang LJ, Fan J and Xia L:
47. Ma LD, Zhou M, Wen SH, Ni C, Jiang LJ, Fan J and Xia L:
48. Mancalha AL, Binato R, Ferreira GM, Du Rocher B and
49. Mancalha AL, Binato R, Ferreira GM, Du Rocher B and
50. Schindler C and Strehlow I: Cytokines and STAT signaling. Adv
51. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE,
Wentzel AL, Xi S and Grands JR: STaT3 activation abrogates
growth factor dependence and contributes to head and neck squamous
42. Ahmed ST and Ivashkiv LB: Inhibition of IL-6 and IL-10
43. Pastuscheck J, Poetzsch J, Morales-Prieto DM, Schleussner E,
Markert UR and Georgiev G: Stimulation of the Jak/STAT
44. Ahmed ST and Ivashkiv LB: Inhibition of IL-6 and IL-10
45. Schindler C and Strehlow I: Cytokines and STAT signaling. Adv
51. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE,
Wentzel AL, Xi S and Grands JR: STaT3 activation abrogates
growth factor dependence and contributes to head and neck squamous
42. Ahmed ST and Ivashkiv LB: Inhibition of IL-6 and IL-10
43. Pastuscheck J, Poetzsch J, Morales-Prieto DM, Schleussner E,
Markert UR and Georgiev G: Stimulation of the Jak/STAT
44. Ahmed ST and Ivashkiv LB: Inhibition of IL-6 and IL-10
45. Schindler C and Strehlow I: Cytokines and STAT signaling. Adv


79. Li HS, Yang CY, Nallaparaju KC, Zhang H, Liu YJ, Goldrath AW.


82. Rozovsky S, Li HS, Yang CY, Nallaparaju KC, Zhang H, Liu YJ, Goldrath AW.


85. Li HS, Yang CY, Nallaparaju KC, Zhang H, Liu YJ, Goldrath AW.


89. Li HS, Yang CY, Nallaparaju KC, Zhang H, Liu YJ, Goldrath AW.


